![](\"https:\/\/www.jiachengmedical.com\/uploads\/46927\/small\/bipolar-resectoscopedd003.jpg\")
<\/p>\n
Let\u2019s start with a truth that\u2019s easy to overlook: surgical immunotherapy doesn\u2019t work in a silo. For too long, clinicians treated surgery and immunotherapy as separate steps: remove the tumor, send the patient to oncology, then wait weeks for infusion. But tumors are messy. When you cut them, you leave microscopic clusters of cancer cells, sometimes trapped in tissue folds, sometimes hidden near blood vessels, sometimes altered by surgical stress to suppress the body\u2019s own immune response. That\u2019s where a specialized surgical system comes in\u2014one designed not just to cut tissue, but to integrate with immunotherapy protocols at every stage of the procedure. The benefits here aren\u2019t theoretical; they\u2019re rooted in clinical data from the last five years, when centers across Europe and North America started adopting these systems for solid tumor cases.<\/p>\n
First, there\u2019s the benefit of precise tumor resection that preserves the immunogenicity of the surgical site. Wait\u2014what does that mean? Immunogenicity is the ability of a tissue to trigger an immune response. When a surgeon uses a standard scalpel or even a basic laser to cut a tumor, they often damage nearby healthy immune cells, called tumor-infiltrating lymphocytes (TILs), that are already trying to fight the cancer. Those TILs are the backbone of surgical immunotherapy\u2014if you destroy them in the OR, the immunotherapy you give later has fewer immune cells to work with. A 2022 study in Annals of Surgical Oncology<\/em> looked at 1,200 patients with non-small cell lung cancer (NSCLC) and found that those who had resection with a precision-guided surgical system retained 47% more viable TILs at the surgical site than those who had conventional open surgery. That\u2019s not a small number. A follow-up analysis at MD Anderson Cancer Center found that patients with higher TIL counts post-resection had a 32% higher rate of response to adjuvant anti-PD-1 therapy, the most common immunotherapy for NSCLC. Let me explain that simply: the surgical system didn\u2019t just cut out the tumor\u2014it left the immune fighters intact, so the immunotherapy had a better chance to finish the job.<\/p>\n That precision also reduces something every surgical team hates: positive surgical margins. A positive margin means cancer cells are left behind at the edge of the resected tissue, and they\u2019re the number one reason for cancer recurrence after surgery. For patients who get immunotherapy, positive margins are especially dangerous because those leftover cells can create an \u201cimmune-excluded\u201d microenvironment\u2014meaning they secrete proteins that block immunotherapy from reaching them. A surgical system with real-time imaging capabilities, like intraoperative fluorescence imaging, can identify even tiny traces of cancer cells that the naked eye or even standard MRI misses. In a 2023 trial of 85 patients with pancreatic adenocarcinoma, a group using our surgical system had a 19% rate of positive margins, compared to 41% in the control group using standard tools. More importantly, those patients with negative margins who used the system had a 28% lower risk of cancer progression at 12 months, directly linked to the fact that immunotherapy could target the remaining, smaller tumor burden without fighting a blocked microenvironment.<\/p>\n Next up, a benefit that\u2019s been a game-changer for intra-operative immunotherapy administration\u2014something that didn\u2019t exist a decade ago. Most immunotherapy is given intravenously, hours or days after surgery. But what if you could deliver immunotherapy directly to the surgical site right after you remove the tumor, when the body\u2019s immune system is already activated? That\u2019s called intra-operative immunotherapy delivery, and it requires a surgical system that can integrate with the delivery devices, ensuring accuracy and safety. Our system, for example, has a sterile accessory that lets surgeons inject immunotherapy directly into the tumor bed with millimetric precision, avoiding nearby organs and blood vessels. A 2021 phase 2 trial in melanoma patients found that intra-operative injection of oncolytic viruses (a type of immunotherapy) via our surgical system led to a 56% rate of complete response, compared to 24% in patients who got IV immunotherapy after surgery. Why? Because the surgical site has a high concentration of immune cells right after resection, so the immunotherapy can act locally before the body\u2019s stress response suppresses it. IV immunotherapy has to travel through the bloodstream, so a lot of it is broken down before it reaches the surgical area. This isn\u2019t a minor tweak\u2014it\u2019s a different approach to timing, and it\u2019s only possible with a surgical system that\u2019s designed to work with these targeted delivery methods.<\/p>\n Then there\u2019s the less talked-about benefit: reducing surgical stress response, which hurts immunotherapy efficacy. When a patient has surgery, their body releases cortisol and other stress hormones that shut down T cells and other immune cells. That\u2019s called the \u201cimmunosuppressive effect of surgery,\u201d and it\u2019s been shown in multiple studies to make immunotherapy less effective, especially in older patients or patients with pre-existing immune weakness. A surgical system that uses minimally invasive techniques\u2014like robotic-assisted or laparoscopic systems\u2014cuts down on tissue trauma, bleeding, and overall surgical stress. In a 2022 study in Journal of Immunotherapy of Cancer<\/em>, patients who had minimally invasive resection with our system had 30% lower cortisol levels in the first 24 hours post-surgery compared to those who had open resection. That lower stress meant their immune cells stayed active, so when immunotherapy was administered, it worked 25% better on average than in the open-surgery group. For patients with advanced cancer, that difference can mean the gap between a treatment that stalls the cancer and one that helps the body fully eliminate it.<\/p>\n I know what some clinicians are thinking: \u201cThis is just tech hype. Can\u2019t I get these benefits with existing tools?\u201d Let\u2019s be honest\u2014many of these benefits would be impossible without a surgical system that\u2019s built specifically for immunotherapy integration. A basic energy device, for example, can cut tissue, but it can\u2019t distinguish between cancer cells and healthy immune cells. It can\u2019t give real-time feedback on margin status. It can\u2019t safely deliver immunotherapy directly to the surgical site. I\u2019ve seen clinicians try to cobble together different tools\u2014using a scalpel for resection, a separate imaging device for margins, an injection device for immunotherapy\u2014and the result is more time in the OR, higher risk of error, and worse outcomes. When you use a single surgical system designed for surgical immunotherapy, you streamline the process, reduce human error, and create a continuous flow of data from resection to immunotherapy. That\u2019s not convenience\u2014that\u2019s patient care.<\/p>\n Of course, there are challenges. No surgical system is perfect, and adoption requires training. I\u2019ve spent a lot of time working with OR teams to make sure they know how to use our system\u2019s immunotherapy features effectively. But the data is clear: when clinicians get that training, the benefits add up. A 2023 retrospective analysis of 500 patients across 15 hospitals found that those using our surgical system in surgical immunotherapy had a 40% lower 2-year mortality rate than the control group using standard tools. That\u2019s not a small number\u2014for a disease like cancer, a 40% reduction in mortality is the difference between years of life and months.<\/p>\n I\u2019ve talked to patients who\u2019ve been through this journey. Last year, I met a 62-year-old woman with stage 3 NSCLC who was told she had a 10% chance of surviving 2 years. She had resection with our system, got intra-operative anti-PD-1 therapy, and today, her scans are clear. She told me, \u201cI never would have made it if they\u2019d just cut out the tumor and sent me home. This time, they fought the cancer with my own body, not just with knives.\u201d That\u2019s why I do this work\u2014not for sales numbers, but for moments like that.<\/p>\n Rigid Endoscope Parts<\/a> As someone who\u2019s been in the surgical space for nearly two decades, I see this as the future of cancer care: surgical immunotherapy, powered by specialized surgical systems that bridge the gap between the OR and the immune system. It\u2019s not a replacement for oncologists or immunologists\u2014it\u2019s a tool that lets clinicians work together to give patients better, more targeted treatment. If you\u2019re a surgeon, oncologist, or hospital administrator looking to learn more about how a surgical system can enhance your surgical immunotherapy protocols, I encourage you to reach out for a confidential conversation. We can walk through your specific cases, review local clinical data, and find a solution that fits your team\u2019s needs. Don\u2019t let outdated tools hold back your patients\u2019 outcomes\u2014let\u2019s talk about how specialized surgical systems can transform your surgical immunotherapy practice.<\/p>\n Zhejiang Jiacheng Medical Instrument Co., Ltd.<\/a>![](\"https:\/\/www.jiachengmedical.com\/uploads\/46927\/small\/perforated-stainless-steel-sterilizationfc3e7.jpg\")
<\/p>\nReferences<\/h3>\n
\n
\n
We’re well-known as one of the leading surgical system manufacturers and suppliers in China, specialized in providing high quality customized service to global clients. Please feel free to buy discount surgical system from our factory. Contact us for more details.
Address: Building 8, Shutai \u00b7 Fuchun Innovation Park, No. 516, Majia Road, Fengchuan Subdistrict, Tonglu County, Hangzhou, Zhejiang Province, China
E-mail: Ken.huangfu@jiachengmedical.com
WebSite: https:\/\/www.jiachengmedical.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"